CKChiaki Kawanishi

Chiaki Kawanishi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chiaki Kawanishi has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 August 2012
      • p. 612-5

    [Neuroleptic malignant syndrome (NMS)].

    by Ikuko Kishida, Taku Furuno, Chiaki Kawanishi

  • Comparison of characteristics of suicide attempters with schizophrenia spectrum disorders and those with mood disorders in Japan

    by Makiko Nakagawa, Chiaki Kawanishi, Tomoki Yamada, Kanna Sugiura, Yoko Iwamoto, Ryoko Sato, Satoshi Morita, Toshinari Odawara, Yoshio Hirayasu


  • Open Access

    Characteristics of suicide attempters with family history of suicide attempt: a retrospective chart review

    by Makiko Nakagawa, Chiaki Kawanishi, Tomoki Yamada, Yoko Iwamoto, Ryoko Sato, Hana Hasegawa, Satoshi Morita, Toshinari Odawara, Yoshio Hirayasu

    Background: Family history of suicide attempt is one of the risks of suicide. We aimed at exploring the characteristics of Japanese suicide attempters with and without a family history of suicide attempt.Methods: Suicide attempters admitted to an urban emergency department from 2003 to 2008 were interviewed by two attending psychiatrists on items concerning family history of suicide attempt and other sociodemographic and clinical information. Subjects were divided into two groups based on the presence or absence of a family history of suicide attempt, and differences between the two groups were subsequently analyzed.Results: Out of the 469 suicide attempters, 70 (14.9%) had a family history of suicide attempt. A significantly higher rate of suicide motive connected with family relations (odds ratio 2.21, confidence interval 1.18–4.17,p< .05) as well as a significantly higher rate of deliberate self-harm (odds ratio 2.51, confidence interval 1.38–4.57,p< .05) were observed in patients with a family history of suicide compared to those without such history. No significant differences were observed in other items investigated.Conclusion: The present study has revealed the characteristics of suicide attempters with a family history of suicide attempt. Further understanding of the situation of such individuals is expected to lead to better treatment provision and outcomes, and family function might be a suitable focus in their treatment.


  • Open Access

    Dopamine D2 Receptor Gene Polymorphisms Are Associated with Suicide Attempt in the Japanese Population

    by Akira Suda, Chiaki Kawanishi, Ikuko Kishida, Ryoko Sato, Tomoki Yamada, Makiko Nakagawa, Hana Hasegawa, Daiji Kato, Taku Furuno, Yoshio Hirayasu

    Background: Some reports have suggested the involvement of the D2 dopaminergic function in the expression of suicidal behavior. Here, we examined associations between suicide attempts and two kinds of functional polymorphisms in the dopamine D2 receptor (DRD2) gene, namely, TaqIA and –141C Ins/Del. Methods: Subjects included 120 suicide attempters and 123 unrelated volunteers. Those who attempted suicide were severely injured and were transferred to the emergency unit in our university hospital. To determine each genotype, we performed polymerase chain reaction and restriction fragment length polymorphism analyses. Results: We found significant differences in genotypic and allelic frequencies of –141C Ins/Del and TaqIA polymorphisms between suicide attempters and healthy controls (–141C Ins/Del, p = 0.01; TaqIA,p = 0.036). The Ins allele of –141C Ins/Del was significantly more frequent in suicide attempters (p = 0.011), as well as the A2 allele of TaqIA (p = 0.017). Haplotype analysis revealed no significant linkage disequilibrium between –141C Ins/Del and TaqIA polymorphisms (D′ = 0.226, r2 = 0.016, p = 0.10). Conclusions: These findings suggest that DRD2 gene polymorphisms may be involved in the biological susceptibility to suicide.


  • Open Access

    Psychiatric assessment of suicide attempters in Japan: a pilot study at a critical emergency unit in an urban area

    by Tomoki Yamada, Chiaki Kawanishi, Hana Hasegawa, Ryoko Sato, Akiko Konishi, Daiji Kato, Taku Furuno, Ikuko Kishida, Toshinari Odawara, Mitsugi Sugiyama, et al.

    Background: The incidence of suicide has increased markedly in Japan since 1998. As psychological autopsy is not generally accepted in Japan, surveys of suicide attempts, an established risk factor of suicide, are highly regarded. We have carried out this study to gain insight into the psychiatric aspects of those attempting suicide in Japan. Methods: Three hundred and twenty consecutive cases of attempted suicide who were admitted to an urban emergency department were interviewed, with the focus on psychosocial background and DSM-IV diagnosis. Moreover, they were divided into two groups according to the method of attempted suicide in terms of lethality, and the two groups were compared. Results: Ninety-five percent of patients received a psychiatric diagnosis: 81% of subjects met the criteria for an axis I disorder. The most frequent diagnosis was mood disorder. The mean age was higher and living alone more common in the high-lethality group. Middle-aged men tended to have a higher prevalence of mood disorders. Conclusion: This is the first large-scale study of cases of attempted suicide since the dramatic increase in suicides began in Japan. The identification and introduction of treatments for psychiatric disorders at emergency departments has been indicated to be important in suicide prevention.


    • 28 October 2007
      • p. 331-5

    [Drug-induced neuroleptic malignant syndrome].

    by Chiaki Kawanishi, Taku Furuno, Ikuko Kishida

  • Unexpectedly high prevalence of akathisia in cancer patients

    by Chiaki Kawanishi, Hideki Onishi, Daiji Kato, Ikuko Kishida, Taku Furuno, Makoto Wada, Yoshio Hirayasu

    Objectives: Complications of neuropsychiatric disorders are often detected in cancer patients. Adjustment disorders, depression, or delirium are common psychiatric disorders in these patients, and drug-induced neuropsychiatric problems are sometimes referred for psychiatric consultation. Prochlorperazine and other antiemetic drugs that are phenothiazine derivates are also reported to cause akathisia due to the blockade of the dopamine receptor in the central nervous system, but the prevalence of akathisia in patients undergoing cancer treatment has not been reported. This study seeks to explore the prevalence of such drug-induced syndromes (e.g., akathisia) in this population. Methods: This present study was a prospective study. The subjects of this study were 483 consecutive patients with cancer who had been referred to the Department of Psychiatry in Kanagawa Prefecture Cancer Center from February 1, 2004, to November 30, 2005. Trained psychiatrists conducted a nonstructured psychiatric interview and neurologic examination to establish psychiatric diagnoses according to DSM-IV and the presence or absence of drug-induced extra pyramidal symptoms. The past and current medications used in their cancer treatment were also examined in detail for an accurate evaluation. Results: A psychiatric diagnosis was made in 420 (87.0%) of the 483 cancer patients examined, and akathisia, a drug-induced movement disorder, was unexpectedly prevalent among the patients; 20 of 420 (4.8%) patients had developed akathisia from an antiemetic drug, prochlorperazine. Significance of results: Diagnosing such adverse drug reactions may be difficult due to complicating factors in cancer treatment, and the inner restlessness observed in akathisia is likely to be regarded as a symptom of a primary psychiatric disorder. The authors suggest that oncologists should optimize the use of antiemetic drugs and be aware of akathisia as a possible complication of cancer treatment.


  • Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome

    by Daiji Kato, Chiaki Kawanishi, Ikuko Kishida, Taku Furuno, Kyoko Suzuki, Hideki Onishi, Yoshio Hirayasu

    Neuroleptic malignant syndrome (NMS) is one of the most serious adverse reactions to antipsychotic medications. We accumulated data on Japanese NMS patients and, in a study designed to examine the effects of drug metabolism on the occurrence of NMS, tested the possibility of association between NMS and CYP2D6 polymorphisms.


  • Pharmacogenetic Aspects of Neuroleptic Malignant Syndrome

    by Chiaki Kawanishi, Ikuko Kishida, Taku Furuno, Daiji Kato, Leif Bertilsson

    Neuroleptic malignant syndrome (NMS), a potentially life-threatening adverse reaction to neuroleptic drugs, is characterized by hyperthermia, extrapyramidal signs, altered consciousness, and autonomic disturbances. Even atypical antipsychotic drugs, considered to carry less risk of adverse reactions than conventional agents, nonetheless can cause NMS. While central dopaminergic pathways have been regarded as pivotal in NMS onset, mechanisms underlying NMS generally remain unclear -rendering prediction or prevention of NMS impossible. Genetic factors predisposing to NMS have been suggested in addition to acquired risk factors, and recent progress in pharmacogenetics and pharmacogenomics permits molecular genetic investigation of adverse drug reactions. Case-control association studies of functional polymorphisms of the dopamine D2 receptor gene have suggested putative mutation sites and a haplotype possibly influencing susceptibility to NMS. Polymorphic alleles of cytochrome P450 2D6 that encode defective enzymes permitting accumulation of excessive plasma neuroleptic drug concentrations also have been examined in relation to NMS susceptibility. Several genes or polymorphisms may contribute to NMS occurrence to a certain extent. Additionally, NMS may represent multiple conditions with shared symptoms but different causative mechanisms. Genetic studies are difficult in NMS because of its low incidence. However, accumulation of genetic information correlated with clinical information for individual patients, as well as more extensive genetic studies, are needed for better understanding of NMS and safer psychopharmacotherapy.